Why Calumet Stock Flopped on Friday

An earnings report that fell notably short of profitability expectations was the main factor behind Calumet (NASDAQ: CLMT) stock's double-digit decline on Friday. Clearly expressing their dissatisfaction with the oil products company's performance, they traded out of the shares to leave them with an almost 11% loss that trading session.

Calumet released its fourth-quarter and full-year 2025 results before market open on Friday. These showed that the company's sales were just under $1.04 billion in the prior period, up 9% year over year. It also managed to trim its net loss under generally accepted accounting principles (GAAP), which came in at $37 million, or $0.43 per share, against fourth-quarter 2024's $40.7 million.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

Although Calumet topped the average analyst estimate for revenue ($1.02 billion), it badly missed the consensus for per-share net loss of $0.22.

Two of the company's three reporting divisions reported erosion in their non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) for the period. Montana/Renewables flipped to a $5.4 million adjusted EBITDA loss from the year-ago profit of $12.4 million. Performance brands also declined, to $5.4 million from $16.3 million. On a brighter note, specialty products and solutions rose to $88.5 million from $51.9 million.

Characterizing all of 2025 as a "defining year," for Calumet, CEO Todd Borgmann said that the company made significant improvements to its operations. He said it enacted around $100 million in cost reductions and cleaned up its balance sheet. In his words, this has "positioned the company for its next phase of growth."

I think every stock should be given a chance to turn things around, but aside from the decent revenue increase, I'm not seeing enough evidence of improvement with Calumet just yet. I'd sit on the sidelines with this stock until we get indications that it's heading onto a firmer growth path.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Calumet wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.